Jorge Alatorre Alexander
@JorgeAlatorreA1
Thoracic Oncologist and Clinical Researcher. Head of the Thoracic Oncology Clinic at INER México City, Private practice ABC Santa Fé & ONCARE. IPADE.
I feel humbled to belong to this family of thoracic oncologists. I feel grateful for the friendship of this community. @marinagarassino: you deserve all the best this life can bring to you, happiness and love. ❤️
Empatía que cambia al mundo… Niña mostrando a sus amigos en la escuela su nueva pierna protésica.♥️😊
ALAT 2025: the leading respiratory congress in Latin America. Honored to collaborate with pulmonologists, thoracic surgeons, pathologists, and multidisciplinary teams to build bridges across the region in lung cancer care. #ALAT @RespiraINER @SMNYCT @IASLC
#Podcast #ASCO2025 #TOPpulmón #ScienceLink Chicago 2025: lo mejor en cáncer de pulmón Dr. Jorge A. Alatorre (@JorgeAlatorreA1) y Dr. Santiago Viteri (@DrViteri) buff.ly/UdDPnwu
In the VERITAS trial, biopsy of indeterminate pulmonary lesions with navigational bronchoscopy was noninferior to that with transthoracic needle biopsy and led to fewer complications. Full trial results and Research Summary: nej.md/43uWPqY
In this episode of the @IASLC podcast, Lung Cancer Considered, I am joined by Drs. @NarjustFlorezMD @CharuAggarwalMD @FordePatrick to discuss the most impactful lung cancer studies from #ASCO25. Available wherever you download podcasts! iaslc.org/iaslc-news/lun…
It was an honor to join the first meeting of the Pan-American Consortium — a group I hope will help strengthen the Americas beyond borders, through collaboration between countries and institutions, to better serve our patients. 🌎🤝 #LungCancer @DrClaudiomartin @AstraZeneca
~13yrs of neoadjuvant adventure comes to positive conclusion (for now)! In @NEJM today & presented at #ASCO25 5 yr survival for pts w lung cancer that can be removed by surgery is better with just 3 doses of immunotherapy before the operation! nejm.org/doi/full/10.10… #LCSM 1/
#ASCO25 Honored to be invited to speak at the Pan American Cancer Consortia with oncology leaders from LATAM, Canada and US to find solutions to improve MultiDisciplinaryTeam capabilities and collaborations across nations via technology and expertise sharing organized by…
#ASCO25 Dr. @charlesrudin presents interim analysis of DeLLphi-304: randomized phase II study of tarlatamab (DLL3 TCE) vs 2L chemo in #SCLC. Chemo was mostly topotecan; 45% of pts were platinum resistant. Clear OS benefit with HR 0.60 (13.6m vs 8.3m). PFS 4.2 vs 3.7m, HR 0.71.
IMforte: RP3 maintenance lurbi+atezo ES-SCLC CNS+ excluded. Enrolled post #4 chemo-atezo if non-PD. GCSF supported. PFS HR=0.5: 2.1 to 5.5mo OS HR=0.73: 10.6 to 13.2mo (from randomztn) ORR 19.4 vs 10.4mo AEs as expected Bravo: a new standard of care #ASCO25
Do we have a future AI based bio marker for TROP 2? Validation needed!
.@herbloong presents BAY088 (sevabertinib) cohort D/F. HER2 treatment naive/SACT naive. Cohort D, ORR=60.5% DOR 9.2mo (TKD ORR 65%). Cohort F, ORR 59%. AEs mostly GI/EGFR-related, 25% G3 diarrhea. Active drug but note skin/GI tox #ASCO25
Always enjoy discussing the data and the science at the poster sessions. Great to see so many friends at #ASCO25 @DrSanjayPopat @JorgeAlatorreA1 @hannawants2ELCN @clarissamathias @M_Tagliamento @KellyMezaMD @HosseinBorghaei @ThomasW35874311
Presented at #ATS2025: In the VERITAS trial, biopsy of indeterminate pulmonary lesions with navigational bronchoscopy was noninferior to that with transthoracic needle biopsy and led to fewer complications. Full trial results: nej.md/43uWPqY Editorial: Biopsy of…
Honored to receive this recognition by Leaders in Healthcare as the 2025 Rising Star Woman in Healthcare. Gracias Totales! @WomenAs1 @WomensHealthMag @UN_Women